4.7 Article

Ketogenic Diet Treatment of Defects in the Mitochondrial Malate Aspartate Shuttle and Pyruvate Carrier

期刊

NUTRIENTS
卷 14, 期 17, 页码 -

出版社

MDPI
DOI: 10.3390/nu14173605

关键词

mitochondrial disease; epilepsy; hepatopathy; aspartate glutamate carrier 1 deficiency; AGC1; citrin deficiency; Citrullinemia; treatment; modified Atkins diet; serine

资金

  1. Children's Research Center
  2. Austrian Science Fund [FWF 4704-B]
  3. BMBF (German Federal Ministry of Education and Research) [01GM1906B]
  4. PerMiM Personalized Mitochondrial Medicine [01KU2016A]
  5. E-Rare project GENOMIT: Mitochondrial Disorders: from a world-wide registry to medical genomics, toward molecular mechanisms and new therapies [01GM1207]
  6. Austrian Science Fund (FWF) [I4695-B]
  7. German Research Foundation/Deutsche Forschungsgemeinschaft [DI 1731/2-2]
  8. Elterninitiative Kinderkrebsklinik e.V. (Dusseldorf, Germany) [701900167]
  9. Swiss National Science Foundation [320030_176088]
  10. [ERAPERMED2019-310]
  11. Swiss National Science Foundation (SNF) [320030_176088] Funding Source: Swiss National Science Foundation (SNF)
  12. Austrian Science Fund (FWF) [I4695] Funding Source: Austrian Science Fund (FWF)

向作者/读者索取更多资源

Defects in the mitochondrial malate aspartate shuttle system and mitochondrial pyruvate carrier 1 are associated with neurological phenotypes and hepatopathic-neuropsychiatric phenotypes. Ketogenic diets and carbohydrate-restricted/fat-enriched diets are effective interventions. Early (genetic) diagnosis is crucial for initiating proper treatment.
The mitochondrial malate aspartate shuttle system (MAS) maintains the cytosolic NAD+/NADH redox balance, thereby sustaining cytosolic redox-dependent pathways, such as glycolysis and serine biosynthesis. Human disease has been associated with defects in four MAS-proteins (encoded by MDH1, MDH2, GOT2, SLC25A12) sharing a neurological/epileptic phenotype, as well as citrin deficiency (SLC25A13) with a complex hepatopathic-neuropsychiatric phenotype. Ketogenic diets (KD) are high-fat/low-carbohydrate diets, which decrease glycolysis thus bypassing the mentioned defects. The same holds for mitochondrial pyruvate carrier (MPC) 1 deficiency, which also presents neurological deficits. We here describe 40 (18 previously unreported) subjects with MAS-/MPC1-defects (32 neurological phenotypes, eight citrin deficiency), describe and discuss their phenotypes and genotypes (presenting 12 novel variants), and the efficacy of KD. Of 13 MAS/MPC1-individuals with a neurological phenotype treated with KD, 11 experienced benefits-mainly a striking effect against seizures. Two individuals with citrin deficiency deceased before the correct diagnosis was established, presumably due to high-carbohydrate treatment. Six citrin-deficient individuals received a carbohydrate-restricted/fat-enriched diet and showed normalisation of laboratory values/hepatopathy as well as age-adequate thriving. We conclude that patients with MAS-/MPC1-defects are amenable to dietary intervention and that early (genetic) diagnosis is key for initiation of proper treatment and can even be lifesaving.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据